Leroy Odile
European Malaria Vaccine Initiative, Artillerivej 5, Copenhague 2300S Danemark.
Bull Acad Natl Med. 2007 Oct;191(7):1249-59; discussion 1259-60.
During the last 10 years the development of a malaria vaccine has attracted an increasing amount of attention both from the political sector and from financial investors. This has led to a number of major scientific and technological advances, but much remains to be done. Numerous potential target antigens are under investigation, and most research is focusing on a subunit vaccine. Irradiated attenuated sporozoites are also a promising approach, even if major technological and regulatory challenges remain to be overcome. Barriers to vaccine development include an inadequate understanding of certain aspects of host-parasite biology and protective immune responses. Other challenges are to increase the antigenicity of some antigens, and to optimize the quality of the immune response. However, research funding remains the main obstacle.
在过去十年中,疟疾疫苗的研发引起了政界和金融投资者越来越多的关注。这带来了一些重大的科学技术进步,但仍有许多工作要做。众多潜在的靶抗原正在研究中,并且大多数研究都集中在亚单位疫苗上。即使仍有重大的技术和监管挑战有待克服,辐照减毒子孢子也是一种有前景的方法。疫苗研发的障碍包括对宿主-寄生虫生物学和保护性免疫反应某些方面的理解不足。其他挑战是提高一些抗原的抗原性,并优化免疫反应的质量。然而,研究资金仍然是主要障碍。